BACKGROUND: Many benign biliary diseases (BBD) can be treated with fully covered, self-expandable metal stents (FCSEMS) but stent migration occurs in up to 35.7 %. The aim of this study was to prospectively assess the rate of, safety and effectiveness and stent migration of a new biliary FCSEMS with an anti-migration flap (FCSEMS-AF) in patients with BBD. PATIENTS AND METHODS: This was a prospective study from four Italian referral endoscopy centers of 32 consecutive patients (10 females and 22 males; mean age: 60.1 ± 14.8 years; range: 32-84 years) with BBD who were offered endoscopic placement of a FCSEMS-AF as first-line therapy. RESULTS: Were 24 strictures and 8 leaks. Stent placement was technically successful in 32/32 patients (100 %). Immediate clinical improvement was seen in all 32 patients (100 %). One late stent migration occurred (3.3 %). FCSEMS-AF were removed from 30 of the 32 patients (93.7 %) at a mean (± SD) of 124.4 ± 84.2 days (range: 10-386 days) after placement. All patients remained clinically and biochemically well at 1- and 3-month follow-up. One patient (3.3 %) with a post-laparoscopic cholecystectomy stricture developed distal stent migration at 125 days. CONCLUSION: This new FCSEMS with anti-migration flap seems to be a safe and effective first-line treatment option for patients with BBD.
BACKGROUND: Many benign biliary diseases (BBD) can be treated with fully covered, self-expandable metal stents (FCSEMS) but stent migration occurs in up to 35.7 %. The aim of this study was to prospectively assess the rate of, safety and effectiveness and stent migration of a new biliary FCSEMS with an anti-migration flap (FCSEMS-AF) in patients with BBD. PATIENTS AND METHODS: This was a prospective study from four Italian referral endoscopy centers of 32 consecutive patients (10 females and 22 males; mean age: 60.1 ± 14.8 years; range: 32-84 years) with BBD who were offered endoscopic placement of a FCSEMS-AF as first-line therapy. RESULTS: Were 24 strictures and 8 leaks. Stent placement was technically successful in 32/32 patients (100 %). Immediate clinical improvement was seen in all 32 patients (100 %). One late stent migration occurred (3.3 %). FCSEMS-AF were removed from 30 of the 32 patients (93.7 %) at a mean (± SD) of 124.4 ± 84.2 days (range: 10-386 days) after placement. All patients remained clinically and biochemically well at 1- and 3-month follow-up. One patient (3.3 %) with a post-laparoscopic cholecystectomy stricture developed distal stent migration at 125 days. CONCLUSION: This new FCSEMS with anti-migration flap seems to be a safe and effective first-line treatment option for patients with BBD.
Authors: Peter B Cotton; Glenn M Eisen; Lars Aabakken; Todd H Baron; Matt M Hutter; Brian C Jacobson; Klaus Mergener; Albert Nemcek; Bret T Petersen; John L Petrini; Irving M Pike; Linda Rabeneck; Joseph Romagnuolo; John J Vargo Journal: Gastrointest Endosc Date: 2010-03 Impact factor: 9.427
Authors: Marc F Catalano; Jeffrey D Linder; Suku George; Eduardo Alcocer; Joseph E Geenen Journal: Gastrointest Endosc Date: 2004-12 Impact factor: 9.427
Authors: Michel Kahaleh; Vinay Sundaram; Steven L Condron; Sarah A De La Rue; Joshua D Hall; Jeffrey Tokar; Charles M Friel; Eugene F Foley; Reid B Adams; Paul Yeaton Journal: Gastrointest Endosc Date: 2007-02-26 Impact factor: 9.427
Authors: Michel Kahaleh; Brian Behm; Bridger W Clarke; Andrew Brock; Vanessa M Shami; Sarah A De La Rue; Vinay Sundaram; Jeffrey Tokar; Reid B Adams; Paul Yeaton Journal: Gastrointest Endosc Date: 2008-03 Impact factor: 9.427
Authors: Michel Kahaleh; Alan Brijbassie; Amrita Sethi; Marisa Degaetani; John M Poneros; David E Loren; Thomas E Kowalski; Divyesh V Sejpal; Sandeep Patel; Laura Rosenkranz; Kevin N McNamara; Isaac Raijman; Jayant P Talreja; Monica Gaidhane; Bryan G Sauer; Peter D Stevens Journal: J Clin Gastroenterol Date: 2013-09 Impact factor: 3.062
Authors: Arthur Schmidt; Tilman Pickartz; Markus M Lerch; Fabrizio Fanelli; Fausto Fiocca; Pierleone Lucatelli; Fabrizio Cereatti; Albrecht Hoffmeister; Werner van Steenbergen; Matthias Kraft; Benjamin Meier; Karel Caca Journal: United European Gastroenterol J Date: 2016-09-07 Impact factor: 4.623